OSE Immunotherapeutics SA
PAR:OSE
OSE Immunotherapeutics SA
Accumulated Depreciation
OSE Immunotherapeutics SA
Accumulated Depreciation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accumulated Depreciation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Accumulated Depreciation
-€2.7m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Accumulated Depreciation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Nanobiotix SA
PAR:NANO
|
Accumulated Depreciation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Accumulated Depreciation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Inventiva SA
PAR:IVA
|
Accumulated Depreciation
-€12.4m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Accumulated Depreciation
-€24.7m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-13%
|
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
See Also
What is OSE Immunotherapeutics SA's Accumulated Depreciation?
Accumulated Depreciation
-2.7m
EUR
Based on the financial report for Jun 30, 2024, OSE Immunotherapeutics SA's Accumulated Depreciation amounts to -2.7m EUR.
What is OSE Immunotherapeutics SA's Accumulated Depreciation growth rate?
Accumulated Depreciation CAGR 5Y
-46%
Over the last year, the Accumulated Depreciation growth was -39%. The average annual Accumulated Depreciation growth rates for OSE Immunotherapeutics SA have been -40% over the past three years , -46% over the past five years .
You don't have any saved screeners yet